Contact
Please use this form to send email to PR contact of this press release:
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
TO:
Please use this form to send email to PR contact of this press release:
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
TO: